Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2014 / Cilt: 60 - Sayı: 2

Bone Morphogenetic Protein Levels in Osteoarthritis

Osteoartritte Kemik Morfogenik Protein Düzeyleri

Pages
117–120
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As to urine samples, it was found that levels of TGF?-1 and BMP7 were below the minimum detection limit proposed by the ELISA method in the patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The modern treatment approach for osteoarthritis aims at suppressing the inflammation by antagonizing such proinflammatory cytokines.
📊
Key Findings & Data:Material and Methods: A total of 41 patients with gonarthrosis, with grade 3 or 4 knees according to Kellgren-Lawrence Grading, and 50 healthy volunteers were included in the study.
💡
Conclusion & Impact:As to urine samples, it was found that levels of TGF?-1 and BMP7 were below the minimum detection limit proposed by the ELISA method in the patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The modern treatment approach for osteoarthritis aims at suppressing the inflammation by antagonizing such proinflammatory cytokines. More complicated approaches are expected to come to the forefront in the future that focus on such signals as bone morphogenetic proteins (BMPs) of the transforming growth factor (TGF)-beta superfamily and alleviate or antagonize the destruction process. These proteins are associated with many cellular functions, such as proliferation, differentiation, and apoptosis. We investigated the BMP levels in the serum and urine samples of patients with osteoarthritis. Material and Methods: A total of 41 patients with gonarthrosis, with grade 3 or 4 knees according to Kellgren-Lawrence Grading, and 50 healthy volunteers were included in the study. Visual analog scale was used for the assessment of pain. Levels of BMP7, BMP6, BMP4, and TGF-?1 were determined by ELISA method based on the serums obtained from the blood samples routinely taken from the patients as well as urine samples of 24 hours. Results: We evaluated the serum and urine samples of 37 patients with gonarthrosis and 29 healthy controls. There was no significant difference between the two groups with regard to age, weight, and height. Levels of serum TGF?-1 and BMP6 were significantly higher in the patients compared to healthy controls (p=0.004, 0.002, respectively). As to urine samples, it was found that levels of TGF?-1 and BMP7 were below the minimum detection limit proposed by the ELISA method in the patients. There was no statistically significant difference between the two groups with regard to levels of BMP4 and BMP6 in the urine (p>0.05). Conclusion: Levels of TGF?-1 and BMP6 were higher in the patients compared to the controls. We think that more frequent examination of BMP levels in serum and urine samples, which are closely associated with the overall process of osteoarthritis, may guide future treatment studies.

Özet

Amaç: Osteoartritin günümüzdeki tedavisi proinflamatuvar sitokinleri antagonize ederek inflamasyonu baskılamaya yöneliktir. İleride dönüştürücü büyüme faktörü (TGF)-beta ailesinden olan kemik morfogenik proteinler (KMP) gibi sinyalleri içeren, harabiyet sürecini azaltan daha karmaşık yöntemlere odaklanılması beklenmektedir. Bu proteinler proliferasyon, farklılaşma, apoptosis gibi pek çok hücre fonksiyonu ile ilişkilidir. Çalışmamızda osteoartrit hastalarının serum ve idrarlarında KMP seviyeleri araştırılmıştır.Gereç ve Yöntemler: Çalışmaya dizleri Kellgren-Lawrence skalasına göre evre 3-4 olan 41 gonartroz hastası ve 50 sağlıklı gönüllü alınmıştır. Ağrı değerlendirmesinde Vizüel Analog Skala (VAS) kullanılmıştır. Hastalardan alınan rutin kan örneklerinden sağlanan serumlar ve 24 saatlik idrar örneklerinden KMP6, KMP7 , KMP4 ve TGF?-1 düzeyleri ELIZA yöntemiyle belirlenmiştir.Bulgular: Yirmi dokuz kontrol, 37 gonartroz hastasına ait serumidrar örnekleri değerlendirilmiştir. Hasta-kontrol grupları yaş, boy, kilo yönünden benzerdi. Hasta grubunda serum TGF?-1 ve KMP 6 düzeyleri kontrol grubuna göre daha yüksekti (sırasıyla p=0,004, 0,002). Hasta grubun idrar TGF?-1 ve KMP7 düzeyleri ELIZA metodunda önerilen minimum tespit edilir düzeyden daha düşüktü. İdrar KMP4 ve KMP6 düzeyleri arasında rakamsal farklılık gözlense de kontrol ve hasta grubu arasında anlamlı istatistiksel fark bulunmadı (p>0,05).Sonuç: Hasta grubunda serum TGF?-1 ve KMP6 düzeyleri daha yüksek bulunmuştur. Osteoartrit süreciyle yakın ilişkisi bulunan KMP düzeylerinin, daha fazla sayıda serum ve idrar örneklerinde incelenmesinin, ileride tedaviye yönelik olarak yapılacak çalışmalara yol gösterici olabileceğini düşünmekteyiz.

🔖

Cite This Article

DİNÇEL, A. S., KARASU, A. U., BOZKURT, S., TAŞ, N. (2022). Bone Morphogenetic Protein Levels in Osteoarthritis. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 60 - Sayı: 2, 117–120. https://ajindex.com/articles/628811

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Atay B. Osteoartrit. In: Beyazova M, Kutsal G.Y, editors. Fiziksel Tıp ve Rehabilitasyon, Güneş Kitabevi, Ankara. 2011:2533-62.
  2. Nakase T, Miyaji T, Tomita T, Kaneko M, Kuriyama K, Myoui A, et al. Localization of bone morphogenetic protein-2 in human osteoarthritic cartilage and osteophyte. Osteoarthritis Cartilage 2003;11:278-84. [CrossRef] Tardif G, Pelletier JP, Boileau C, Martel-Pelletier J. The BMP anta- gonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study. Osteoarthritis Cartilage 2009;17:263-70. [CrossRef] Grgurevic L, Macek B, Erjavec I, Mann M, Vukicevic S. Urine release of systemically administered bone morphogenetic protein hybrid molecule. J Nephrol 2007;20:311-9.
  3. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005;328:651-7. [CrossRef] Biver E, Hardouin P, Caverzasio J. The ''bone morphogenic prote- ins'' pathways in bone and joint diseases: Translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Fac- tor Rev 2013;24:69-81. [CrossRef] Badlani N, Oshima Y. Use of Bone Morphogenic Protein-7 as a Treatment for osteoarthritis. Clin Orthop Relat Res 2009;467:3221-9. [CrossRef] Kuran B. Osteoartritte subkondral kemikteki değişiklikler. Tur J Geri- atrics 2011;14:57-61.
  4. Uchino M, Izumi T, Tominaga T, Wakita R, Minehara H, Sekiguchi M et al. Growth factor expression in the steophytes of the human femoral head in osteoarthritis. Clin Orthop Relat Res 2000;377:119-25. [CrossRef] Bailey AJ, Mansell JP, Sims TJ, Banse X. Biochemical and mechani- cal properties of subchondral bone in osteoarthritis. Biorheology 2004;41:349-58.
  5. Szpalski M, Gunzburg R. Recombinant human bone morphoge- netic protein-2: A novel osteoinductive alternative to autogenous bone graft ? Acta Orthop Belg 2005;71:133-48.
  6. Herrera B, Inman GJ. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 2009;10:20. [CrossRef] Buijs JT, Henriquez NV, van Overveld PG, Horst G van der, Que I, Schwaninger R, et al. Bone morphogenetic protein 7 in the de- velopment and treatment of bone metastases from breast cancer. Cancer Res 2007;67:8742-51. [CrossRef] Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, et al. BMP7, a putative regulator of epithelial home- ostasis in the human prostate, is a potent in